CONTACT: MICHAEL SONDERGARD
8798 John Pappajohn Pavilion
Iowa City IA 52242
Release: July 22, 1999
UI study evaluates drug to prevent recurrence of stroke
IOWA CITY, Iowa -- Patients who have had stroke, transient
ischemic attack, or both peripheral vascular disease and stroke are invited
to participate in a University of Iowa Health Care study evaluating a drug
that might prevent recurrence of further vascular disease.
The trial -- called Blockade of the GP IIB/IIIA Receptor
to Avoid Vascular Occlusion (BRAVO) -- will evaluate whether the anti-platelet
drug, lotrafiban, taken in combination with aspirin, will reduce the occurrence
of death, stroke, heart attack or revascularization surgery. Lotrafiban prevents
excessive blood clot formation in patients experiencing the onset of stroke
or other vascular disease.
"Half the participants in BRAVO will receive the drug
with aspirin and half will receive a placebo with aspirin," said Patricia
Davis, M.D., UI associate professor of neurology. "It's a double-blind study,
which means participants will not know whether they are receiving the drug
or receiving the placebo."
Davis, who is principal investigator of the UI Health
Care portion of the international trial, said participants will be followed
for two years, with a visit to the UI Hospitals and Clinics required once
every three months.
There is no cost for the drug or for any trial-related
patient visits during the study.
To qualify, stroke patients must have experienced stroke
or transient ischemic attack within 30 days before enrollment. There is no
such limit for patients with a history of stroke and peripheral vascular disease.
The trial's coordinator is Lynn Vining.
For more information about enrolling in the study,
patients should call UI Health Access at (319) 384-4442 or toll-free, (800)
777-8442. Physicians are encouraged to call UI Consult at
(319) 384-8008 or toll-free, (800) 322-8442.